Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276331 | 1.00 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3KCNH2GAA | |
| SCHEMBL7296171 | 0.86 | NPSR1 (0.46) | GAANPSR1EPHX2 | |
| SCHEMBL18494973 | 0.84 | EPHX1 (0.34) | SLC6A4SLC6A2SLC6A3GAANPSR1 | |
| SCHEMBL18469983 | 0.84 | NPSR1 (0.45) | GAANPSR1CYP2D6EPHX2 | |
| Hydrochloric Acid SCHEMBL28933506 | 0.83 | GNAI3 (0.33) | SLC6A4SLC6A2SLC6A3GAANPSR1 | |
| SCHEMBL8484000 | 0.74 | ALDH1A1 (0.35) | SLC6A4SLC6A2SLC6A3CYP2D6EPHX2 | |
| Hydrochloric Acid SCHEMBL8483997 | 0.73 | L3MBTL1 (0.36) | SLC6A4SLC6A2SLC6A3CYP2D6EPHX2 | |
| SCHEMBL24359375 | 0.73 | GAA (0.44) | GAANPSR1CYP2D6 | |
| SCHEMBL4646897 | 0.73 | SLC6A2 (0.42) | SLC6A4SLC6A2GAANPSR1 | |
| SCHEMBL6628285 | 0.72 | L3MBTL1 (0.46) | NPSR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989634-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| EP-1685102-A4 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| EP-1685102-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047251-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129346-A1 | Melanocortin receptor agonists | MC1R, MC3R, MC5R | SLC6A4 386/4885SLC6A2 272/4885SLC6A3 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.